Medical treatment of pruritus

Bibliography

• Weisshaar E, Szepietowski JC, Darsow U, European Guideline for Chronic Pruritus. 2010. Available from: http://www.euroderm.org/images/stories/guidelines/EDF-Guideline-on-Chronic-Pruritus.pdf Acta DermatoVeneraol 2012, in press
   Google Scholar
• Metz M, Ständer S. Chronic pruritus – pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010;24:1249-60
   PubMed Web of Science ®Google Scholar
• Ständer S, Raap U. Weisshaar E, et al. [Pathogenesis of Pruritus]. J Dtsch Dermatol Ges 2011;9:456–63
   PubMedGoogle Scholar
• Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011;11:420-7
   PubMed Web of Science ®Google Scholar
• Dalgard F, Svensson A, Holm JO, Self-reported skin morbidity in Oslo. Associations with socio-demographic factors among adults in a cross-sectional study. Br J Dermatol 2004;151:452-7
   PubMed Web of Science ®Google Scholar
• Ständer S, Schäfer I, Phan NQ, Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010;221:229-35
   PubMed Web of Science ®Google Scholar
• Matterne U, Apfelbacher CJ, Loerbroks A, Prevalence, correlates and characteristics of chronic pruritus. A population-based cross-sectional study. Acta Derm Venereol 2011;91:674-9
   PubMed Web of Science ®Google Scholar
• Vogelgsang L, Loerbroeks A, Apfelbacher CJ, Incidence of chronic pruritus and its determinants: results from a population-based study. Exp Dermatol 2012;21:e1-e48
   PubMedGoogle Scholar
• Ständer S, Luger T. Itch in atopic dermatitis - pathophysiology and treatment. Acta Dermatovenerol Croat 2010;18:289-96
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Dalgard F. Epidemiology of itch. Adding to the burden of skin morbidity. Acta Derm Venereol 2009;89:339-50
   PubMed Web of Science ®Google Scholar
• Weisshaar E. Pruritus and psoriasis: an often, but frequently underestimated relation. Hautarzt 2012;63:547-52
   PubMed Web of Science ®Google Scholar
• Dawn A, Papoiu AD, Chan YH, Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 2009;160:642-4
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Apfelbacher CJ, Jäger G, Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006;155:957-64
   PubMed Web of Science ®Google Scholar
• Sommer F, Hensen P, Bockenholt B, Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol 2007;78:510-16
   Google Scholar
• Ständer S, Weisshaar E, Mettang T, Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007;87:291-4
   PubMed Web of Science ®Google Scholar
• Ständer S, Streit M, Darsow U, Guideline: diagnostic and therapeutic procedures in chronic pruritus. J Dtsch Dermatol Ges 2006;4:350-70
   PubMedGoogle Scholar
• Siepmann D, Weishaupt C, Luger TA, Evaluation of the German guideline for chronic pruritus: results of a retrospective study on 385 patients. Dermatology 2011;223:374-80
   PubMed Web of Science ®Google Scholar
• Schmelz M, Schmidt R, Bickel A, Specific C-receptors for itch in human skin. J Neurosci 1997;17:8003-8
   PubMed Web of Science ®Google Scholar
• Ständer S, Schmelz M. Chronic itch and pain – similarities and differences. Eur J Pain 2006;10:473-8
   PubMed Web of Science ®Google Scholar
• Namer B, Carr R, Johanek LM, Separate peripheral pathways for pruritus in man. J Neurophysiol 2008;100:2062-9
   PubMed Web of Science ®Google Scholar
• Johanek LM, Meyer RA, Hartke T, Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 2007;27:7490-7
   PubMed Web of Science ®Google Scholar
• Darsow U, Pfab F, Valet M, Pruritus and atopic dermatitis. Clin Rev Allergy Immunol 2011;4:237-44
   Google Scholar
• Abadia Molina F, Burrows NP, Jones RR, Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol 1992;127:344-51
   PubMed Web of Science ®Google Scholar
• Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003;295:2-7
   PubMed Web of Science ®Google Scholar
• Papoiu AD, Wang H, Nattkemper L, A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects. Neuropeptides 2011;45:417-22
   PubMed Web of Science ®Google Scholar
• Tominaga M, Tengara S, Kamo A, Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009;55:40-6
   PubMed Web of Science ®Google Scholar
• Grewe M, Vogelsang K, Ruzicka T, Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol 2000;114:1108-12
   PubMed Web of Science ®Google Scholar
• Denda M, Sokabe T, Fukumi-Tominaga T, Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol 2007;127:654-9
   PubMed Web of Science ®Google Scholar
• Takaoka A, Arai I, Sugimoto M, Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005;516:180-1
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-17
   PubMed Web of Science ®Google Scholar
• Cornelissen C, Marquardt Y, Czaja K, IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012;129:426-33. e1-8
   PubMed Web of Science ®Google Scholar
• Nobbe S, Dziunycz P, Mühleisen B, IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol 2012;92:24-8
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Mommert S, Gschwandtner M, The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol 2009;123:619-25
   PubMed Web of Science ®Google Scholar
• Andrew D, Craig AD. Spinothalamic lamina 1 neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001;4:72-7
   PubMed Web of Science ®Google Scholar
• Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448:700-3
   PubMed Web of Science ®Google Scholar
• Sun YG, Zhao ZQ, Meng XL, Cellular basis of itch sensation. Science 2009;325:1531-4
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Ständer S, Gieler U, Development of a German language questionnaire for assessing chronic pruritus (AGP-questionnaire): background and first results. Hautarzt 2011;62:914-27
   PubMed Web of Science ®Google Scholar
• Schneider G, Driesch G, Heuft G, Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin Exp Dermatol 2006;31:762-7
   PubMed Web of Science ®Google Scholar
• O' Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005;18:333-40
   PubMedGoogle Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, EAACI/ Galen Guideline: management of urticaria. Allergy 2005;61:321-31
   Web of Science ®Google Scholar
• Schulz S, Metz M, Siepmann D, Antipruritic efficiency of a high-dosage antihistaminic therapy. Results of a retrospectively analyzed case series. Hautarzt 2009;60:564-8
   PubMed Web of Science ®Google Scholar
• Apfelbacher CJ, Ebert I, Scheidt R, H1 antihistamines for eczema. A systematic review. Cochrane Skin Group Protocols. 2009. Available from: http://summaries.cochrane.org/CD007770/h1-antihistamines-for-eczema
   Google Scholar
• Kawashima M, Tango T, Nogushi T, Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multi-center, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003;148:1212-21
   PubMed Web of Science ®Google Scholar
• Murota H, Kitaba S, Tani M, Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritus skin diseases. Allergol Int 2010;59:345-54
   PubMedGoogle Scholar
• Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage 2004;28:396-11
   PubMed Web of Science ®Google Scholar
• Misery L. Gabapentin in dermatology. Dermatology 2005;211:79-80
   PubMed Web of Science ®Google Scholar
• Kanitakis J. Brachioradial pruritus. report of a new case responding to gabapentin. Eur J Dermatol 2006;16:311-12
   PubMed Web of Science ®Google Scholar
• Yesudian PD, Wilson NJE. Efficiency of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005;141:1507-9
   PubMed Web of Science ®Google Scholar
• Gunal AI, Ozalp G, Yoldas TK, Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9
   PubMed Web of Science ®Google Scholar
• Ehrchen J, Ständer S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol 2008;58(2 Suppl):S36 7
   PubMed Web of Science ®Google Scholar
• Porzio G, Aielli F, Efficiency of pregabalin in the management of cetoximab-related itch. J Pain Symptom Manage 2006;32:397-8
   PubMed Web of Science ®Google Scholar
• Phan NQ, Bernhard JD, Luger TA, Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010;19:58-65
   Google Scholar
• Phan NQ, Lotts T, Antal A, Systemic kappa opioid receptor (KOR) agonists in the treatment of chronic pruritus: a review. Acta DermatoVenereol 2012; In press
   Web of Science ®Google Scholar
• Wikström B, Gellert R, Ladefoged SD, Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16:3742-7
   PubMed Web of Science ®Google Scholar
• Kumagai H, Ebata T, Takamori K, Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25:1251-7
   PubMed Web of Science ®Google Scholar
• Davis MP, Frandsen JL, Walsh D, Mirtazapine for pruritus. J Pain Symptom Manage 2003;25:288-91
   PubMed Web of Science ®Google Scholar
• Tefferi A, Von Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002;99:27
   Google Scholar
• Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998;16:121-4
   PubMed Web of Science ®Google Scholar
• Biondi M, Arcangeli T. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000;69:165-6
   PubMed Web of Science ®Google Scholar
• Zylicz Z, Krajnik M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003;26:1105-12
   PubMed Web of Science ®Google Scholar
• Ständer S, Bockenholt B, Schürmeyer-Horst F, Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-armed, prove-off-concept study. Acta Derm Venereol 2009;89:45-51
   PubMed Web of Science ®Google Scholar
• Schworer H, Hartmann H, Ramadori G, Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7
   PubMed Web of Science ®Google Scholar
• Raderer M, Muller C, Scheithauer W, Ondansetron for pruritus due to cholestasis. N Engl J Med 1994;330:40
   Google Scholar
• Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995;10:140
   PubMed Web of Science ®Google Scholar
• Albares M P, Betlloch I, Guijarro J, Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 2003;148:376-7
   PubMed Web of Science ®Google Scholar
• O' Donohue JW, Haigh C, Ondansetron in the treatment of cholestasis: a randomised controlled trial. Gastroenterology 1997;112:A1349
   Web of Science ®Google Scholar
• Muller C, Pongratz S, Pidlich J, Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865 70
   PubMed Web of Science ®Google Scholar
• Larijani GE, Goldberg ME, Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996;16:958-60
   PubMed Web of Science ®Google Scholar
• Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001;18:346-57
   PubMed Web of Science ®Google Scholar
• Ashmore SD, Jones CH, Newstead CG, Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000;35:827-31
   PubMed Web of Science ®Google Scholar
• Murphy M, Reaich D, Pai P, A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003;148:314-17
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Dunker N, Röhl FW, Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol 2004;13:298-04
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. Br J Dermatol 1995;132:795-9
   PubMed Web of Science ®Google Scholar
• Siepmann D, Luger TA, Ständer S, Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges 2008;6:941-6
   PubMedGoogle Scholar
• Staab D, Diepgen TL, Fartasch M, Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multi-center, randomised controlled trial. BMJ 2006;332:933-8
   PubMed Web of Science ®Google Scholar
• Evers A, P, Duller P, Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. Acta Derm Venereol 2009;89:57-63
   PubMed Web of Science ®Google Scholar
• Van Oos-Medendorp H, Ros WJG, Eland-de Kok CM, Effectiveness of the nursing programme ”Coping with itch”: a randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 2007;156:1235-44
   PubMed Web of Science ®Google Scholar
• Bathe A, Matterne U, Dewald M, Educational multidisciplinary training programme for patients with chronic pruritus. Acta Derm Venereol 2009;89:498-01
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale (VAS), numerical rating scale (NRS) and verbal rating scale (VRS) in 471 chronic pruritus patients. Acta Derm Venereol 2011; In press
   Web of Science ®Google Scholar
• Ständer S, Blome C, Breil B, Assessment of pruritus - current standards and implications for clinical practice : consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP). Hautarzt 2012l;63:521-31
   PubMed Web of Science ®Google Scholar
• Reich A, Heisig M, Phan NQ, Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2011; doi: 10.2340/00015555-1265
   PubMed Web of Science ®Google Scholar
• Blome C, Augustin M, Siepmann D, Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 2009;161:1143-8
   PubMed Web of Science ®Google Scholar
• Duval A, Dubertret L. Aprepitant as an antipruritic agent?. N Engl J Med 2009;361:1415-16
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Fratto ME, Santini D, Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010;18:1229-30
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363:397-8
   PubMed Web of Science ®Google Scholar
• Ständer S, Siepmann D, Herrgott I, Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010;5:e10968
   PubMed Web of Science ®Google Scholar
• Walter M, Kottke T, Stark H. The histamine H4 receptor: targeting inflammatory disorders. Eur J Pharmacol 2011;668:1-5
   PubMed Web of Science ®Google Scholar
• Shin N, Covington M, Bian D, INCB38579, a novel and potent histamine H4 receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur J Pharmacol 2012;675:47-56
   PubMed Web of Science ®Google Scholar
• Suwa E, Yamaura K, Oda M, Histamine H4 receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. Eur J Pharmacol 2011;667:383-8
   PubMed Web of Science ®Google Scholar
• Rossbach K, Wendorff S, Sander K, Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009;18:57-63
   PubMed Web of Science ®Google Scholar